Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

▎药明康德内容团队编辑日前，阿斯利康（AstraZeneca）与安进（Amgen）合作开发的“first-in-class”单抗Tezspire（tezepelumab）针对伴有鼻息肉的慢性鼻窦炎（CRSwNP）患者进行的WAYPOINT临床3期试验 ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

公开资料显示，Tezepelumab是阿斯利康与安进共同开发的一款first-in-class单克隆抗体，可抑制胸腺基质淋巴细胞生成素 (TSLP)。TSLP是一种关键的上皮细胞因子，位于多种炎症级联反应的上游，与哮喘、CRSwNP、慢性阻塞性肺疾病 ...

在最新的试验结果中，Tezspire治疗组展现出了统计学和临床意义上显著的改善，这标志着在慢性鼻窦炎及鼻息肉治疗方法上的一大突破。这项研究结果为进一步的临床应用奠定了基础，同时也为医务人员提供了新的武器，以更有效地帮助患者。

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...